Michael J. Mancino, M.D.

           Michael Mancino, M.D.

CONTACT INFO
Psychiatric Research Institute, Center for Addiction Research
4301 West Markham, Slot # 848

Little Rock, Arkansas 72205
(501) 526-8442
Fax: (501) 526-7816

mjmancino@uams.edu

 

EDUCATION
University of Akron, BS Summa cum Laude, 1984 in Life Sciences, Akron, Ohio

Northeastern Ohio Universities College of Medicine, MD, 1988, Rootstown, Ohio

 

POSTGRADUATE TRAINING

1988-1989       Intern General Surgery, University Hospital, Louisville, Kentucky 

1993-1997       Resident, Neurological Surgery, University of Mississippi Medical Center, Jackson, Mississippi

1999-2000       NIMH Postdoctoral Mental Health Services Research Fellow, University of Arkansas for Medical Sciences, Little Rock, Arkansas

2000-2003       Resident in Psychiatry, University of Arkansas for Medical Sciences, Little Rock, Arkansas

2003-2004       Chief Resident, Arkansas State Hospital, Little Rock, Arkansas

2003-2004       NIMH Mental Health Services Postdoctoral Research Fellow, University of Arkansas for Medical Sciences, Little Rock, Arkansas

BOARD STATUS   
Diplomate American Board of Psychiatry and Neurology June 2005 #55053
American Society of Addiction Medicine Certification December 2006 #622456
Diplomate American Board of Addiction Medicine May 2009 #000940 

HONORS            
Two University of Akron Association Academic Scholarships (1982-83 and 1983-84)

Jason, Sumner and Conme Academic Scholarship (1984)

Specht Medical Education Foundation of College of Medicine Academic Scholarship (1986-87)

Scholarship to attend American Psychiatric Association’s Research Colloquium for Junior Investigators. Langley Psychiatric Institute. San Francisco, California (May 2003).
Outstanding Resident Poster. UAMS Department of Psychiatry Annual Poster Session. “Generic Health-related Quality of Life in a Veteran Population with Post Traumatic Stress Disorder”. June 2003.

Abbott Achievement Award for Excellence in Medical Student Teaching (2003)

Participant in Third Annual Career Development Institute for Mental Healthcare Research. Cosponsored by Stanford and Western Psychiatric Institute, Pittsburgh, Pennsylvania, (April 2004).

Alpha Omega Alpha, Housestaff Member, (2004)

Participant in Future Leaders in Psychiatry Symposium, Grand Lakes Orlando, FL, Sponsored by Dr. Charles Nemeroff and Emory University. (May 22 – 25, 2008)

College on Problems of Drug Dependence Early Career Investigator Award (June, 2008)

ACADEMIC APPOINTMENTS

2006-current                Assistant Professor, Department of Psychiatry, University of Arkansas for Medical Sciences

2005-current                Program Director, Substance Abuse Treatment Clinic, University

                                    of Arkansas for Medical Sciences

2006-current                Director, Resident Research Track, University of Arkansas for

                                    Medical Sciences

2009-current                Director, Buprenorphine Outpatient Treatment Program,

                                    University of Arkansas for Medical Sciences, Chemical

                                    Dependency Outpatient Program

2005-2009                   Director, Buprenorphine Outpatient Treatment Program, Central

                                    Arkansas Veterans Healthcare System, Special Treatment Services

2003-2006                   Instructor, Department of Psychiatry, University of Arkansas for

                                    Medical Sciences

2004-2009                   Staff psychiatrist, Central Arkansas Veterans Healthcare System, Mental Health Clinic

PROFESSIONAL EXPERIENCE 

1990               Research Assistant, Department of Surgery, University of Louisville, Louisville, Kentucky

1990-1992       Research Assistant, Kentucky Lions Eye Institute, Department of Ophthalmology, University of Louisville, Louisville, Kentucky

1991-1992       Medical House Officer, Jefferson Alcohol Drug Abuse Center, Louisville, Kentucky

1992-1993       Staff Physician, Community Bio Resources, Inc., Louisville, Kentucky

1992-1993       Staff Physician, Our Lady of Peace Hospital, Louisville, Kentucky

1997-2000       Med-Val Disability Evaluations, Claude Earle Fox, M.D., PO Box 630, Charleston, MS 38921

1998-1999       Research Assistant, Medicaid Administrative Project, Brenda Booth, Ph.D., Department of Psychiatry, University of Arkansas for Medical Sciences, Little Rock, Arkansas

PUBLICATIONS In Review       

1. Oliveto, A., Poling, J., Mancino, M., Feldman, Z., Cubells,  J., Pruzinsky, R., Gonsai, K., Cargile, C., Sofuoglu, M., Chopra, M., Gonzalez-Haddad, G., Carroll, K., Kosten, T. Effect of Dose, Alcohol Dependence Diagnosis and Cocaine Dependence Severity on Disulfiram Treatment of Cocaine Dependence in Methadone-Stabilized Patients. Addiction. 

2. Mancino, M.J., Gentry, W.B., Feldman, Z., Mendelson, J.E., Oliveto, A. Characterizing methamphetamine withdrawal in recently abstinent methamphetamine users: A pilot field study. Journal of Addictive Diseases.

PUBLICATIONS

Normal
0

false
false
false

MicrosoftInternetExplorer4

st1:*{behavior:url(#ieooui) }

/* Style Definitions */
table.MsoNormalTable
{mso-style-name:”Table Normal”;
mso-tstyle-rowband-size:0;
mso-tstyle-colband-size:0;
mso-style-noshow:yes;
mso-style-parent:””;
mso-padding-alt:0in 5.4pt 0in 5.4pt;
mso-para-margin:0in;
mso-para-margin-bottom:.0001pt;
mso-pagination:widow-orphan;
font-size:10.0pt;
font-family:”Times New Roman”;
mso-ansi-language:#0400;
mso-fareast-language:#0400;
mso-bidi-language:#0400;}

1. Mancino, M., Curran, G., Xiatong, H., Allee, E., Humphreys, K., Booth, B. Predictors of Attrition from a National Sample of Methadone Maintenance Patients. In Press: American Journal of Drug and Alcohol Abuse.

2. Mancino, M.J., Feldman, Z., McGaugh, J., and Oliveto, A. Effect of PTSD diagnosis and contingency management procedures on cocaine use in opioid dependent cocaine abusers maintained on low- vs. high-dose LAAM. In press: The American Journal on Addictions.  

3. McGaugh, J., Mancino, M.J., Feldman, Z., Chopra, M.P., Gentry, W.B., Cargile, C., Oliveto, A.O. Open Label Pilot Study of Modafinil for Methamphetamine Dependence. The Journal of Clinical Psychopharmacology. 2009, Oct; 29(5): 488-91.

4. Chopra MP, Feldman Z, Mancino MJ, Oliveto A. Sex and opioid maintenance dose influence response to naloxone in opioid-dependent humans: A retrospective analysis. Pharmacology, Biochemistry and Behavior. 2008, Oct; 90(4):787-96.

5. Mancino MJ, Pyne JM, Tripathi S, Constans J, Roca V., Freeman T: Quality-Adjusted Health Status in Veterans with Post-Traumatic Stress Disorder. J Nerv Ment Dis. 2006 Nov; 194(11):877-879.

6. Smith GR, Burnam MA, Mosley CL, Hollenberg JA, Mancino M, Grimes W: “Measuring Substance Abuse Treatment and Outcomes: The Reliability and Validity of the Substance Abuse Outcomes Module”.  Psychiatr Serv. 2006 Oct; 57(10):1452-60.

7. Kramer TL, Evans RB, Landes R, Mancino MJ, Booth BM, and Smith GR: Comparing Outcomes of routine care for depression: the dilemma of case-mix adjustment. J. Behav Health Services Res. 2001 Aug; 28(3): 287-300.

8. Mancino MJ, Cunningham MR, Davidson P, Fulton RL: Identification of the Motor Vehicle Accident Victim Who Abuses Alcohol: An Opportunity to Reduce Trauma. Journal of Studies on Alcohol. 57(6):652-658, 1996.

9. Kulkarni PS, Mancino MJ: Studies on Intraocular Inflammation Produced by Intavitreal Human Interleukins in Rabbits. Experimental Eye Research. 56(3): 275-279, 1993.

10. Fulton RL, Mancino MJ, Flynn WJ, Bowles D, Cryer HM: Brain Injury Causes Loss of Cardiovascular Response to Hemorrhagic Shock. Journal of Investigative Surgery.  6(2): 117-131, 1993.

11. Fulton RL, Everman D, Mancino MJ, Raque G: Ritual Head Computed Tomography may Unnecessarily Delay Lifesaving Trauma Care. Surgery, Gynecology and Obstetrics. 176(4): 327-332, 1993.

12.  Ohia EO, Mancino MJ, Kulkarni PS: Effects of Steroids and Immunosuppressive Drugs on Endotoxin-uveitis in Rabbits. Journal of Ocular Pharmacology. 8(4): 295-307, 1992.

13.  Mancino MJ, Ohia EO, Kulkarni PS: A Comparative Study between Cod Liver Oil and Liquid Lard Intake on Intraocular Pressure in Rabbits. Prostaglandins, Leukotrienes and Essential Fatty Acids. 45(3): 239-243, 1992.

PROFESSIONAL ASSOCIATIONS

President, Arkansas Chapter, American Society of Addiction Medicine 2007-2009

College on Problems of Drug Dependence, Associate Member since January 2006
American Society of Addiction Medicine, Member since 2005
Arkansas Medical Society, Member since 200
American Psychiatric Association, Member since 2000
Arkansas Psychiatric Association, Member since 2000

COMMITTEES

Chairman, Process Action Team Central Arkansas Veterans Healthcare System, Mental  Health Services Line. Title: Co-morbid treatment processes for patients with mood and anxiety disorders and substance abuse. July 2004-June 2005.
Member, Resident Research Committee. University of Arkansas for Medical Sciences April, 2006-ongoing

Member, Medical Staff Health Committee. University of Arkansas for Medical Sciences January, 2007-ongoing

Member, Process Action Team Central Arkansas Veterans Healthcare System, High Risk Medications, April 2007- ongoing.

Member, Process Action Team Central Arkansas Veterans Healthcare System, Substance Abuse Treatment/Mental Health Integration, July 2007- October, 2007.

TEACHING ACTIVITIES

Development and Implementation of Review of Clinical Neurology for Psychiatrist Course with PGY-II Psychiatry Residents during outpatient psychiatry rotation at the Central Arkansas Veterans Health Service. Preparation for Part I Psychiatry Boards. 2004-2008.

Didactic on Neuropsychiatric Case Conference: “Review of the limbic system” for PGY-II, III and IV Psychiatry Residents. 2005-present; University of Arkansas for Medical Sciences (UAMS).

Didactics on Neuropsychiatric Case Conference: “Review of typical PRITE Neurology Questions” for PGY-II, III and IV Psychiatry Residents, 2005-present, UAMS.

Didactic on Neuropsychiatric Case Conference: “Review of Aphasias” for PGY-II, III and IV Psychiatry Residents. 2006-present, UAMS.

Clinical Correlation Lecture on Methadone Maintenance, Behavioral Sciences Course, Second Year Medical Students. Annually since 2007, UAMS.

Didactic on Neuropsychiatric Case Conference: “Peripheral Nerve Disorders and Muscle Disorders” for PGY- II, III and IV Psychiatry Residents. 2007-present, UAMS.

UAMS Department of Family Medicine Teaching Conference: “Limit Setting”, 2007-present.

COSIG In-service: Buprenorphine update for the treatment of opiate addiction. Division of Health and Human Services, Conference Call, March 21, 2007.

Resident’s Conference Department of Internal Medicine: “Behavioral and Clinical Effects of Cocaine Intoxication”. May 7, 2007, UAMS.

Team Based Learning Module on Substance Use Disorders for Third year medical students rotating on Psychiatry. Didactic presented every 6 weeks throughout the academic year starting August, 2007.

Didactic on Addiction: “Opiate withdrawal and treatment” for PGY-III and IV Psychiatry Residents. 2007-present, UAMS.

Clinical Aspects of Alcohol and Sedative/Hypnotic Related Disorders, Behavioral Sciences Course, Second Year Medical Students. 2008-present, UAMS.

Clinical Aspects of Substance Abuse and Dependence, Behavioral Sciences Course, Second Year Medical Students. 2008-present, UAMS.

COSIG In-service: Buprenorphine update for the treatment of opiate addiction. Division of Health and Human Services, Teleconference Call, January 21, 2009.

UAMS Department of Pathology Teaching Conference: “Physician Impairment”, annually starting in May, 2009.

Didactic on Addiction: “Methadone Maintenance Treatment” for PGY-III and IV Psychiatry Residents. July 9, 2009 UAMS.

Didactic on Addiction: “Acute Management of Substance Use Disorders” for PGY-I Psychiatry Residents. July 23, 2009 UAMS.

RESEARCH ACTIVITIES

“Center for Translational Neuroscience”

Principal Investigator: Edgar Garcia-Rill, Ph.D.
Agency: NIH, National Center for Research Resources
Type: P20 (RR20146) Period: August 1, 2009-July 31, 2014
This Center of Excellence award supports five projects and six core facilities.  The research involves 1) novel treatment for Alzheimer’s disease, 2) treatment for relapse to drug abuse, 3) long-term effects of low birth weight, 4) novel treatment for tobacco dependence, and 5) mechanisms of leptin action, obesity and sleep.  The role of the Director is to organize a mentoring program for young clinician scientists towards independently funded research programs.  However, the mentors, including the applicant, have access to the Core Facilities. During the initial funding period, Mentees and new Recruits secured >$13 million in new awards, generated 130 articles and chapters, and made 4 major breakthroughs.
Role: Project 2 leader
 

“Clinical Efficacy of Disulfiram in Methadone-Maintained Patients”

Principal Investigator: Alison Oliveto-Beaudoin, Ph.D.

Agency: National Institute on Drug Abuse

Type: R01 (DA13441, Years 1-11) Period: May 1, 2001 to June 30, 2011.

This study examines the efficacy of three doses of Disulfiram relative to placebo on cocaine in methadone maintained patients also receiving Cognitive Behavioral Therapy.

Role: Co-investigator

 

“Opiate Antagonist Discrimination: Model of Withdrawal”

Principal Investigator: Alison Oliveto-Beaudoin, Ph.D.

Agency: National Institute on Drug Abuse

Type: RO1 (DA010017, Years 7-12) Period: March 1, 2006 to January 31, 2011

This competitive renewal is a series of 4 studies using the naloxone (NX) novel-response discrimination procedure in opioid-dependent humans that build upon our demonstration that this procedure can be used successfully as a model of opiate withdrawal (OW) to examine non-opioid mechanisms underlying this phenomenon.

Role: Co-investigator

 

“Improving Combined Buprenorphine-Behavioral Treatment”

Principal Investigator: Warren K. Bickel, Ph.D.

Agency: National Institute on Drug Abuse

Type: R01 (DA12997, years 6-10) Period: March 1, 2005-February 28, 2010

The major goal of this project is to examine the efficacy of modifications to the Community Reinforcement Approach (CRA) with contingency management that make it less costly to provide the context of buprenorphine maintenance treatment of opioid dependence.
Role: Sub-investigator

“Cocaine Pharmacotherapies for Comorbid Populations”

Principal Investigator: Thomas Kosten, M.D.

Agency: National Institute on Drug Abuse

Type: P50 (DA12762, Years 6-10) Period: September 1, 2004-June 30, 2009

This Center is composed of interdisciplinary research projects examining the efficacy of treatments for opioid and/or cocaine dependence in comorbid populations. The research theme of this Center is a planned development of new, effective treatments for cocaine and/or opioid abuse in cocaine abusers who are depressed, have potential perfusion deficits or have dual cocaine and opioid dependence

Role: Project Co-investigator

“Improvement in Specialized Treatment Programs for Substance Abuse Disorders at the Centra Arkansas Veterans Healthcare System”
Principal Writer: Michael J. Mancino M.D.

Agency: Veterans Administration Central Office

Amount: $162,211 for 3 years (2005-2008)

This is a program development proposal to enhance treatment for opiate addiction in the Central Arkansas Veterans Health Care Systems by providing buprenorphine treatment on an outpatient basis. Also provides for training opportunities for physicians to gain exposure and experience with outpatient buprenorphine treatment.